利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

127 条记录 (耗时 0.034 秒)

    MAXIMIZING T-CELL MEMORY AND COMPOSITIONS AND METHODS THEREFOR
    51.
    发明申请
    MAXIMIZING T-CELL MEMORY AND COMPOSITIONS AND METHODS THEREFOR 有权

    公开(公告)号：US20220072045A1

    公开(公告)日：2022-03-10

    申请号：US17525802

    申请日：2021-11-12

    申请人： NantCell ,  Nant Holdings IP, LLC

    发明人： Shahrooz Rabizadeh ,  Kayvan Niazi ,  Patrick Soon-Shiong ,  Hing Wong ,  Wenxin Xu

    IPC分类号： A61K35/17 ,  A61K31/675 ,  C07K14/52 ,  C12N15/86

    摘要： Contemplated treatments and methods produce substantially increased quantities of memory T-cells and a persistent immune response by subcutaneous and/or subdermal co-administration of (1) a vector comprising a recombinant nucleic acid that encodes a cancer associated epitope, a cancer specific epitope, and/or a neoepitope, (2) an immune stimulating cytokine, and (3) a checkpoint inhibitor. Most typically, the co-administration is performed at substantially the same location, preferably within 1-21 days from each other, and the vector is an adenoviral expression vector, for example, included in a viral particle such as an AdV5 virus with a deletion of the E2b gene.

    Multimodal Vector for Dendritic Cell Infection
    53.
    发明申请
    Multimodal Vector for Dendritic Cell Infection 有权

    公开(公告)号：US20210198689A1

    公开(公告)日：2021-07-01

    申请号：US16081014

    申请日：2017-03-20

    申请人： Nant Holdings IP, LLC ,  NantCell, Inc.

    发明人： Patrick Soon-Shiong ,  Kayvan Niazi ,  Shahrooz Rabizadeh

    IPC分类号： C12N15/86 ,  C07K14/705

    摘要： Recombinant viruses and viral nucleic acids are contemplated that provide to the infected cell various regulatory molecules that stimulate T-cell and NK-cell activity and that suppress inhibition of T-cell and NK-cell activity. Most preferably, the virus and viral nucleic acid will further include a human cancer-associated sequence, and especially a sequence that encodes a plurality of cancer associated antigens, cancer specific antigens, and/or patient and tumor specific neoantigens. Especially preferred regulatory molecules include CD80 (B7.1), CD86 (B7.2), CD54 (ICAM-1/BB2), CD11 (LFA-1), and an inhibitor of CTLA-4.